Denali Therapeutics Fda Approval, Food and Drug Administration (FDA) has granted accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier and reach the whole body, including the brain. This voucher was awarded following the FDA's approval of AVLAYAH, an enzyme replacement therapy for Hunter syndrome. 19 hours ago · Denali Therapeutics (Nasdaq: DNLI) agreed to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds. May 21, 2026 · Denali Therapeutics Announces U. The approval was granted to Denali Therapeutics. The voucher was granted after FDA accelerated approval of AVLAYAH for Hunter syndrome in March 2026. Mar 25, 2026 · Avlayah received breakthrough, fast track, priority review, and orphan drug designations and accelerated approval for this indication. Mar 25, 2026 · “The approval of AVLAYAH is a new era for the Hunter syndrome community as we deliver the first FDA-approved therapy designed to cross the brain’s protective barrier for individuals and families living with this debilitating disease. May 18, 2026 · Hedge fund ADAR1 Capital Management made that bet with a $36 million Denali Therapeutics position in Q1. Mar 26, 2026 · Conclusion The FDA approval of AVLAYAH marks the end of the beginning for Denali Therapeutics. bpfwsk, bk4, d8wm, p9gn, ryalcj, vjizs, fjh, j8x, kr, gwqg,